Radiotherapy has, historically, played a central role in the management of acromegaly, and the last 30 years have seen substantial improvements in the technology used in the delivery of radiation therapy. More recently, the introduction of highly targeted radiotherapy, or ‘radiosurgery', has further increased the therapeutic options available in the management of secretory pituitary tumors. Despite these developments, improvements in primary surgical outcomes, an increase in the range and effectiveness of medical therapy options, and long-term safety concerns have combined to dictate that, although still deployed in selected cases, the use of radiotherapy in the management of acromegaly has declined steadily over the past 2 decades. In this article, we review some of the main studies that have documented the efficacy of pituitary radiotherapy on growth hormone hypersecretion and summarize the data around its potential deleterious effects, including hypopituitarism, cranial nerve damage, and the development of radiation-related intracerebral tumors. We also give practical recommendations to guide its future use in patients with acromegaly, generally, as a third-line intervention after neurosurgical intervention in combination with various medical therapy options.

Keywords:
Acromegaly, Radiotherapy, Survival, Hypopituitarism
1.
Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, et al: Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009;94:1509-1517.
2.
Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al: Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:3933-3951.
3.
Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K, et al: AcroBel - the Belgian registry on acromegaly: a survey of the ‘real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol 2007;157:399-409.
4.
Sesmilo G, Gaztambide S, Venegas E, Pico A, Del Pozo C, Blanco C, et al: Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). Pituitary 2013;16:115-121.
5.
Bucci MK, Bevan A, Roach M 3rd: Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin 2005;55:117-134.
6.
Eastman RC, Gorden P, Roth J: Conventional supervoltage irradiation is an effective treatment for acromegaly. J Clin Endocrinol Metab 1979;48:931-940.
7.
Feek CM, McLelland J, Seth J, Toft AD, Irvine WJ, Padfield PL, et al: How effective is external pituitary irradiation for growth hormone-secreting pituitary tumors? Clin Endocrinol (Oxf) 1984;20:401-408.
8.
Eastman RC, Gorden P, Glatstein E, Roth J: Radiation therapy of acromegaly. Endocrinol Metab Clin North Am 1992;21:693-712.
9.
Ho PJ, Jaffe CA, Friberg RD, Chandler WF, Barkan AL: Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors. J Clin Endocrinol Metab 1994;78:1403-1410.
10.
Freda PU, Post KD, Powell JS, Wardlaw SL: Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998;83:3808-3816.
11.
Puder JJ, Nilavar S, Post KD, Freda PU: Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 2005;90:1972-1978.
12.
Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS: Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004;89:1613-1617.
13.
Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, et al: A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010;95:3141-3148.
14.
Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE: Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979;301:1138-1142.
15.
Spagnoli A, Rosenfeld RG: The mechanisms by which growth hormone brings about growth. The relative contributions of growth hormone and insulin-like growth factors. Endocrinol Metab Clin North Am 1996;25:615-631.
16.
Barkan AL, Beitins IZ, Kelch RP: Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 1988;67:69-73.
17.
Daughaday WH, Starkey RH, Saltman S, Gavin JR 3rd, Mills-Dunlap B, Heath-Monnig E: Characterization of serum growth hormone (GH) and insulin-like growth factor I in active acromegaly with minimal elevation of serum GH. J Clin Endocrinol Metab 1987;65:617-623.
18.
Camacho-Hubner C: Assessment of growth hormone status in acromegaly: what biochemical markers to measure and how? Growth Horm IGF Res 2000;10(suppl B):S125-S129.
19.
Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, et al: Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997;82:3187-3191.
20.
Lee CC, Vance ML, Xu Z, Yen CP, Schlesinger D, Dodson B, et al: Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab 2014;99:1273-1281.
21.
Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D: Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90:4465-4473.
22.
Howlett TA, Willis D, Walker G, Wass JA, Trainer PJ; Group UKARS: Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxf) 2013;79:689-699.
23.
Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S: Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One 2012;7:e36411.
24.
van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, et al: Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1,288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012;97:1589-1597.
25.
Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ: Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 2009;160:529-533.
26.
Powell JS, Wardlaw SL, Post KD, Freda PU: Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab 2000;85:2068-2071.
27.
Biermasz NR, van Dulken H, Roelfsema F: Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 2000;85:2476-2482.
28.
Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA: Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 2006;91:1239-1245.
29.
Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, et al: The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 2005;62:210-216.
30.
Castinetti F, Brue T: Gamma knife radiosurgery in pituitary adenomas: why, who, and how to treat? Discov Med 2010;10:107-111.
31.
Jezkova J, Marek J, Hana V, Krsek M, Weiss V, Vladyka V, et al: Gamma knife radiosurgery for acromegaly - long-term experience. Clin Endocrinol (Oxf) 2006;64:588-595.
32.
Attanasio R, Epaminonda P, Motti E, Giugni E, Ventrella L, Cozzi R, et al: Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab 2003;88:3105-3112.
33.
Castinetti F, Taieb D, Kuhn JM, Chanson P, Tamura M, Jaquet P, et al: Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 2005;90:4483-4488.
34.
Pollock BE, Jacob JT, Brown PD, Nippoldt TB: Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg 2007;106:833-838.
35.
Ronchi CL, Attanasio R, Verrua E, Cozzi R, Ferrante E, Loli P, et al: Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10-year follow-up study. Clin Endocrinol (Oxf) 2009;71:846-852.
36.
Roug S, Rasmussen AK, Juhler M, Kosteljanetz M, Poulsgaard L, Heebøll H, Roed H, Feldt-Rasmussen U: Fractionated stereotactic radiotherapy in patients with acromegaly: an interim single-centre audit. Eur J Endocrinol 2010;162:685-694.
37.
Hoybye C, Rahn T: Adjuvant gamma knife radiosurgery in non-functioning pituitary adenomas; low risk of long-term complications in selected patients. Pituitary 2009;12:211-216.
38.
Jagannathan J, Yen CP, Pouratian N, Laws ER, Sheehan JP: Stereotactic radiosurgery for pituitary adenomas: a comprehensive review of indications, techniques and long-term results using the gamma knife. J Neurooncol 2009;92:345-356.
39.
Pollock BE, Cochran J, Natt N, Brown PD, Erickson D, Link MJ, et al: Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys 2008;70:1325-1329.
40.
Sheehan JP, Niranjan A, Sheehan JM, Jane JA Jr, Laws ER, Kondziolka D, et al: Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 2005;102:678-691.
41.
Swords FM, Monson JP, Besser GM, Chew SL, Drake WM, Grossman AB, et al: Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy. Eur J Endocrinol 2009;161:819-828.
42.
Jagannathan J, Sheehan JP, Pouratian N, Laws ER Jr, Steiner L, Vance ML: Gamma knife radiosurgery for acromegaly: outcomes after failed transsphenoidal surgery. Neurosurgery 2008;62:1262-1269, discussion 1269-1270.
43.
Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, et al: Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metab 2000;85:1287-1289.
44.
Castinetti F, Regis J, Dufour H, Brue T: Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol 2010;6:214-223.
45.
Leenstra JL, Tanaka S, Kline RW, Brown PD, Link MJ, Nippoldt TB, et al: Factors associated with endocrine deficits after stereotactic radiosurgery of pituitary adenomas. Neurosurgery 2010;67:27-32, discussion 32-33.
46.
Marek J, Jezkova J, Hana V, Krsek M, Bandurova L, Pecen L, et al: Is it possible to avoid hypopituitarism after irradiation of pituitary adenomas by the Leksell gamma knife? Eur J Endocrinol 2011;164:169-178.
47.
Sicignano G, Losa M, del Vecchio A, Cattaneo GM, Picozzi P, Bolognesi A, et al: Dosimetric factors associated with pituitary function after Gamma Knife Surgery (GKS) of pituitary adenomas. Radiother Oncol 2012;104:119-124.
48.
Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla GK, Ghigo E: Hypopituitarism. Lancet 2007;369:1461-1470.
49.
Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, et al: Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357:425-431.
50.
Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, et al: Mortality in patients with pituitary disease. Endocr Rev 2010;31:301-342.
51.
Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, et al: ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 2009;94:4216-4223.
52.
Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML: Gamma knife surgery for Cushing's disease. J Neurosurg 2007;106:980-987.
53.
Cifarelli CP, Schlesinger DJ, Sheehan JP: Cranial nerve dysfunction following gamma knife surgery for pituitary adenomas: long-term incidence and risk factors. J Neurosurg 2012;116:1304-1310.
54.
Minniti G, Traish D, Ashley S, Gonsalves A, Brada M: Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 2005;90:800-804.
55.
Brada M, Ford D, Ashley S, Bliss JM, Crowley S, Mason M, et al: Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ 1992;304:1343-1346.
56.
Sattler MG, van Beek AP, Wolffenbuttel BH, van den Berg G, Sluiter WJ, Langendijk JA, et al: The incidence of second tumours and mortality in pituitary adenoma patients treated with postoperative radiotherapy versus surgery alone. Radiother Oncol 2012;104:125-130.
57.
Brada M, Burchell L, Ashley S, Traish D: The incidence of cerebrovascular accidents in patients with pituitary adenoma. Int J Radiat Oncol Biol Phys 1999;45:693-698.
58.
Raber J: Unintended effects of cranial irradiation on cognitive function. Toxicol Pathol 2010;38:198-202.
59.
Crossen JR, Garwood D, Glatstein E, Neuwelt EA: Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 1994;12:627-642.
60.
Eiser C: Cognitive deficits in children treated for leukaemia. Arch Dis Child 1991;66:164-168.
61.
Noad R, Narayanan KR, Howlett T, Lincoln NB, Page RC: Evaluation of the effect of radiotherapy for pituitary tumours on cognitive function and quality of life. Clin Oncol (R Coll Radiol) 2004;16:233-237.
62.
Guinan EM, Lowy C, Stanhope N, Lewis PD, Kopelman MD: Cognitive effects of pituitary tumours and their treatments: two case studies and an investigation of 90 patients. J Neurol Neurosurg Psychiatry 1998;65:870-876.
63.
Brummelman P, Elderson MF, Dullaart RP, van den Bergh AC, Timmer CA, van den Berg G, et al: Cognitive functioning in patients treated for nonfunctioning pituitary macroadenoma and the effects of pituitary radiotherapy. Clin Endocrinol (Oxf) 2011;74:481-487.
64.
Brummelman P, Sattler MG, Meiners LC, Elderson MF, Dullaart RP, van den Berg G, et al: Cognitive performance after postoperative pituitary radiotherapy: a dosimetric study of the hippocampus and the prefrontal cortex. Eur J Endocrinol 2012;166:171-179.
65.
de Herder WW: The history of acromegaly. Neuroendocrinology 2016;103:7-17.
66.
Schernthaner-Reiter MH, Trivellin G, Stratakis CA: MEN1, MEN4, and carney complex: pathology and molecular genetics. Neuroendocrinology 2016;103:18-31.
67.
Buchfelder M, Schlaffer S-M: Novel techniques in the surgical treatment of acromegaly: applications and efficacy. Neuroendocrinology 2016;103:32-41.
68.
Chanson P: Medical treatment of acromegaly with dopamine agonists or somatostatin analogs. Neuroendocrinology 2016;103:50-58.
69.
Neggers SJCMM, Muhammad A, van der Lely AJ: Pegvisomant treatment in acromegaly. Neuroendocrinology 2016;103:59-65.
70.
McCabe J, Ayuk J, Sherlock M: Treatment factors that influence mortality in acromegaly. Neuroendocrinology 2016;103:66-74.
71.
Powlson AS, Gurnell M: Cardiovascular disease and sleep-disordered breathing in acromegaly. Neuroendocrinology 2016;103:75-85.
72.
Claessen KMJA, Mazziotti G, Biermasz NR, Giustina A: Bone and joint disorders in acromegaly. Neuroendocrinology 2016;103:86-95.
73.
Dal J, List EO, Jørgensen JOL, Berryman DE: Glucose and fat metabolism in acromegaly: from mice models to patient care. Neuroendocrinology 2016;103:96-105.
74.
Webb SM, Badia X: Quality of life in acromegaly. Neuroendocrinology 2016;103:106-111.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.